S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Forecast, Price & News

$3.12
+0.05 (+1.63%)
(As of 12:26 PM ET)
Compare
Today's Range
$3.01
$3.13
50-Day Range
$2.13
$3.34
52-Week Range
$1.12
$3.50
Volume
129,428 shs
Average Volume
611,208 shs
Market Capitalization
$133.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

Galera Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
152.4% Upside
$7.75 Price Target
Short Interest
Healthy
2.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$212,350 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.66) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

505th out of 1,006 stocks

Pharmaceutical Preparations Industry

243rd out of 492 stocks


GRTX stock logo

About Galera Therapeutics (NASDAQ:GRTX) Stock

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRTX Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Galera Expands Commercial Leadership Team
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Galera Therapeutics (NASDAQ:GRTX) Price Target Cut to $6.00
Analyst Ratings for Galera Therapeutics
Where Galera Therapeutics Stands With Analysts
See More Headlines

GRTX Price History

GRTX Company Calendar

Last Earnings
3/08/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRTX
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+152.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-62,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.28) per share

Miscellaneous

Free Float
39,217,000
Market Cap
$131.73 million
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Dr. J. Mel Sorensen M.D. (Age 65)
    CEO, Pres & Director
    Comp: $820.77k
  • Mr. Christopher Degnan (Age 42)
    Chief Financial Officer
    Comp: $529.35k
  • Mr. Mark J. Bachleda M.B.A. (Age 47)
    Pharm.D., Chief Commercial Officer
    Comp: $476.5k
  • Dr. Robert A. Beardsley M.B.A. (Age 60)
    Ph.D., Co-Founder & COO
  • Dr. Dennis P. Riley Ph.D.
    Chief Scientific Officer, Emeritus
  • Ms. Jennifer Evans Stacey Esq. (Age 57)
    Chief Legal & Compliance Officer and Sec.
  • Dr. Jon T. Holmlund M.D. (Age 65)
    Exec. Officer
  • Ms. Andie Collier
    Sr. VP of Regulatory Affairs
  • Ms. Judy Schnyder
    Sr. VP of Clinical Operations & Data Management
  • Dr. Eugene P. Kennedy F.A.C.S. (Age 53)
    FACS, M.D., Chief Medical Officer













GRTX Stock - Frequently Asked Questions

Should I buy or sell Galera Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTX shares.
View GRTX analyst ratings
or view top-rated stocks.

What is Galera Therapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month target prices for Galera Therapeutics' stock. Their GRTX share price forecasts range from $6.00 to $12.00. On average, they expect the company's share price to reach $7.75 in the next year. This suggests a possible upside of 152.4% from the stock's current price.
View analysts price targets for GRTX
or view top-rated stocks among Wall Street analysts.

How have GRTX shares performed in 2023?

Galera Therapeutics' stock was trading at $1.49 at the beginning of 2023. Since then, GRTX stock has increased by 106.0% and is now trading at $3.07.
View the best growth stocks for 2023 here
.

When is Galera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GRTX earnings forecast
.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

When did Galera Therapeutics IPO?

(GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

What is Galera Therapeutics' stock symbol?

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

Who are Galera Therapeutics' major shareholders?

Galera Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc. (4.89%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.47%), Geode Capital Management LLC (0.46%), Schonfeld Strategic Advisors LLC (0.32%) and State Street Corp (0.19%). Insiders that own company stock include Bioventures Ltd Novartis, Chris Degnan, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund, Linda West, Mark Bachleda and Mel Sorensen.
View institutional ownership trends
.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galera Therapeutics' stock price today?

One share of GRTX stock can currently be purchased for approximately $3.07.

How much money does Galera Therapeutics make?

Galera Therapeutics (NASDAQ:GRTX) has a market capitalization of $131.73 million. The company earns $-62,220,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.

How can I contact Galera Therapeutics?

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The official website for the company is www.galeratx.com. The company can be reached via phone at 610-725-1500 or via email at cdegnan@galeratx.com.

This page (NASDAQ:GRTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -